{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:27Z","timestamp":1755216747861,"version":"3.43.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Neuroblastoma (NBL) is a common pediatric tumor arising from sympathetic ganglion cells. High-risk NBL is based on age, stage, histology, and <jats:italic toggle=\"yes\">MYCN<\/jats:italic> amplification, and is associated with a high mortality rate. The combination of naxitamab (NAX) and granulocyte-macrophage (cerebrospinal fluid) is a new treatment for high-risk and relapsed NBL approved for bone or bone marrow disease. NAX is a monoclonal antibody directed against anti-disialoganglioside, which is overexpressed in neuroblastoma. Under normal circumstances, monoclonal antibodies, such as NAX, cannot cross the blood-brain barrier due to size. We present the case of a patient with high-risk NBL treated with NAX for multiple bony relapses. Unexpectedly, her brain metastasis responded clinically, histologically, and by imaging to the treatment. We believe this is the first documented case of NBL of the brain responding to NAX.<\/jats:p>","DOI":"10.1097\/mph.0000000000002807","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:00:21Z","timestamp":1704704421000},"page":"e188-e190","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma"],"prefix":"10.1097","volume":"46","author":[{"given":"Chinyere","family":"Onyeukwu","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Rush University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Williams","sequence":"additional","affiliation":[{"name":"Loyola University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Seyboth","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Neurosurgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladson","family":"Scaria","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kent","sequence":"additional","affiliation":[{"name":"Medical Director, FibroFighters Foundation, Temecula, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/bjc.2016.302","article-title":"Factors associated with recurrence and survival length following relapse in patients with neuroblastoma","volume":"115","author":"Basta","year":"2016","journal-title":"Br J Cancer"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/cancers12020309","article-title":"Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)","volume":"12","author":"Ladenstein","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40880-015-0038-2","article-title":"Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment","volume":"34","author":"Zhu","year":"2015","journal-title":"Chin J Cancer"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2217\/imt-2016-0021","article-title":"Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy","volume":"8","author":"Horta","year":"2016","journal-title":"Immunotherapy"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3389\/fphys.2020.00914","article-title":"Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders","volume":"11","author":"Lochhead","year":"2020","journal-title":"Front Physiol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/biomedicines9121834","article-title":"Drug delivery challenges in brain disorders across the blood-brain barrier: novel methods and future considerations for improved therapy","volume":"9","author":"Achar","year":"2021","journal-title":"Biomedicines"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/pharmaceutics12010062","article-title":"Antibodies for the treatment of brain metastases, a dream or a reality?","volume":"12","author":"Cavaco","year":"2020","journal-title":"Pharmaceutics"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cyto.2015.05.030","article-title":"GM-CSF: an immune modulatory cytokine that can suppress autoimmunity","volume":"75","author":"Bhattacharya","year":"2015","journal-title":"Cytokine"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/BTT.S267278","article-title":"Monoclonal antibody therapies for high-risk neuroblastoma","volume":"15","author":"Furman","year":"2021","journal-title":"Biol Targets Ther"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:48Z","timestamp":1754337888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002807","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"2023-04-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}